TScan Q2 2026: Narrower Loss, Cash Runway into Q2 2027, and Phase 3 Dosing Begins
TCRX is trading near its 52-week low of $0.716 (8.9% above the low) on light trading volume (0.4× avg).
Summary
TScan Therapeutics posted a reduced net loss for Q2 2026 and extended its cash runway into Q2 2027. The first patient has been dosed in the Phase 3 ALLOHA-2 trial, and positive manufacturing data were shared, marking a pivotal step for its lead TCR-T therapy.
Key Events · Earnings and Guidance · TCRX
-
Q2 2026 Financial Results
The net loss narrowed to $30.4M from $37.0M in Q2 2025, on revenue of $1.1M. R&D expenses fell to $23.4M and G&A to $8.1M, reflecting cost savings from pipeline prioritization.
-
Cash Runway into Q2 2027
Cash and equivalents stood at $100.2M as of June 30, 2026. The runway extends into Q2 2027 but now includes term loan amortization beginning in Q4 2026 after a non-covenant milestone was missed.
-
Phase 3 ALLOHA-2 Trial Initiated
In July 2026, the first patient was dosed in the pivotal study of TSC-101 for heme malignancies. Enrollment completion and topline data are expected by mid-2028.
-
Positive Cohort C Manufacturing Data
Cohort C of the Phase 1 ALLOHA study demonstrated ~90% first-pass manufacturing success with the commercial-ready process, and 79% of patients achieved complete donor chimerism within approximately three weeks of TSC-101 infusion.
Analysis · TCRX · Life Sciences
A narrower net loss of $30.4M—down from $37.0M a year ago—highlights TScan's Q2, driven by lower R&D and G&A spending. Cash of $100.2M funds operations into Q2 2027, though the runway now reflects term loan amortization starting after a missed non-covenant milestone. Dosing the first patient in the pivotal Phase 3 ALLOHA-2 trial marks a key value driver, with topline data expected mid-2028. Positive Cohort C data using a commercial-ready manufacturing process further de-risks the program. At $0.78 per share, the micro-cap valuation amplifies the importance of clinical execution and cash conservation.
At the time of this filing, TCRX was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8M. The 52-week trading range was $0.72 to $2.57. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.